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PI3Kδ and PI3Kγ isoforms have distinct functions in
regulating pro-tumoural signalling in the multiple myeloma
microenvironment
RE Piddock1, N Loughran1, CR Marlein1, SD Robinson2, DR Edwards3, S Yu1, GE Pillinger1, Z Zhou3, L Zaitseva1, MJ Auger4,
SA Rushworth1 and KM Bowles1,4
Phosphoinositide-3-kinase and protein kinase B (PI3K-AKT) is upregulated in multiple myeloma (MM). Using a combination of short
hairpin RNA (shRNA) lentivirus-mediated knockdown and pharmacologic isoform-speciﬁc inhibition we investigated the role of the
PI3K p110γ (PI3Kγ) subunit in regulating MM proliferation and bone marrow microenvironment-induced MM interactions. We
compared this with inhibition of the PI3K p110δ (PI3kδ) subunit and with combined PI3kδ/γ dual inhibition. We found that MM cell
adhesion and migration were PI3Kγ-speciﬁc functions, with PI3kδ inhibition having no effect in MM adhesion or migration assays.
At concentration of the dual PI3Kδ/γ inhibitor duvelisib, which can be achieved in vivo we saw a decrease in AKT phosphorylation at
s473 after tumour activation by bone marrow stromal cells (BMSC) and interleukin-6. Moreover, after drug treatment of BMSC/
tumour co-culture activation assays only dual PI3kδ/γ inhibition was able to induce MM apoptosis. shRNA lentiviral-mediated
targeting of either PI3Kδ or PI3Kγ alone, or both in combination, increased survival of NSG mice xeno-transplanted with MM cells.
Moreover, treatment with duvelisib reduced MM tumour burden in vivo. We report that PI3Kδ and PI3Kγ isoforms have distinct
functions in MM and that combined PI3kδ/γ isoform inhibition has anti-MM activity. Here we provide a scientiﬁc rationale for trials
of dual PI3kδ/γ inhibition in patients with MM.
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INTRODUCTION
Multiple Myeloma (MM), is presently incurable with o50% of
patients surviving over 5 years post diagnosis.1 MM is char-
acterised by the accumulation of monoclonal plasma cells that are
primarily contained within the bone marrow. Current treatments
including proteasome inhibitors, immune modulating drugs and
alkylating agents are effective at reducing the tumour bulk and
alleviating symptoms,2,3 however relapse remains inevitable from
residual disease sequestered within the MM microenvironment. It
is envisaged that improved patient outcomes will come from
novel therapeutic strategies informed by an improved under-
standing of the biology of the disease.4
Phosphoinositide-3-kinases (PI3K) are an enzyme group that
generate phosphatidylinositol 3,4, 5-triphosphate (PIP3). PIP3
provides a membrane docking site for the tyrosine kinase AKT
(also known as protein kinase B), which on binding upregulates
cell survival and proliferation signals. Class 1 group of PI3K
subunits in particular (PI3K α/β/γ/δ) are known to be involved in
the carcinogenesis and chemo-resistance in several cancer types.
PI3Kδ is usually activated by receptor tyrosine kinase signalling,
however PI3Kγ is most commonly found downstream of
G protein-coupled receptors.5–7 PI3K α/β catalytic subunits are
expressed in a wide variety of tissues, whereas PI3Kδ/γ have been
shown to be speciﬁcally enriched in the haematopoietic system.8
The aberrant activation of the PI3K-AKT pathway has been
reported in several blood cancers including acute myeloid
leukaemia, chronic lymphocytic leukaemia and MM.9,10 Inhibition
of pan-PI3K using LY295002- and PI3Kδ-only inhibition using
idelalisib (previously known as CAL-101) has been shown to
downregulate chronic lymphocytic leukaemia and MM cell
survival signals,11 causing malignant cells to become more
sensitive to chemotherapeutic treatment.12,13 Moreover, idelalisib
is currently licensed for the treatment of selected patients with
chronic lymphocytic leukaemia and follicular lymphoma.14 Inter-
estingly, PI3Kγ has been shown to be highly expressed in MM
cells,11 however the exact function of PI3Kγ subunit in the biology
of MM is not yet deﬁned. Using drugs that inhibit PI3Kδ (idelalisib),
PI3Kγ (CZC24832) or both PI3Kδ and PI3Kγ in combination
(duvelisib; previously known as IPI-145) and experiments using
short hairpin RNA (shRNA) knockdown, we investigated the
pharmacological and molecular outcome of targeting PI3Kδ and
PI3Kγ both alone and in combination in MM using in vitro and
in vivo assays.
MATERIALS AND METHODS
Materials
Anti-phosphorylated and pan, AKT, and MAPK antibodies, and PI3Kα/β/γ
antibodies were purchased from Cell Signalling Technology (Cambridge,
MA, USA). Anti-PI3Kδ antibody was purchased from R&D systems (Oxford,
UK). Anti-CD138-PE, anti-CD90-FITC, anti-CD73-PE, anti-CD105-APC anti-
bodies (Cat. 130-098-122, 130095403, 130095182, 130094926) and
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interleukin-6 (IL-6) were purchased from Miltenyi Biotec (Auburn, CA, USA).
Idelalisib, CZC24832, duvelisib were obtained from Selleck Chemicals
(Houston, TX, USA). All other reagents were obtained from Sigma-Aldrich
(St Louis, MO, USA), unless otherwise indicated.
Cell lines and primary samples
The MM-derived cell lines were obtained from the European Collection of
Cell Cultures where they are authenticated by DNA ﬁngerprinting. MM
cell lines were cultured in RPMI 1640 medium supplemented with 10%
foetal bovine serum, penicillin and streptomycin (all obtained from
Invitrogen, Paisley, UK). Primary MM cells were obtained from patients’
bone marrow after informed consent was given in accordance with the
Declaration of Helsinki and under approval from the United Kingdom
National Research Ethics Service (07/H0310/146).
For primary cell isolation, heparinised bone marrow was collected from
volunteers; human bone marrow cells were isolated by histopaque density-
gradient centrifugation and plated in growth media. Non-adherent cells
were removed after 24 h. At 60–80% conﬂuency, adherent cells were
trypsinised and expanded for 3–6 weeks. bone marrow stromal cells
(BMSCs) were checked for positive expression of CD105, CD73 and CD90,
and the lack of expression of CD45 by ﬂow cytometry as previously
described.15 Primary plasma cells were puriﬁed by positive selection using
magnetic-activated cell sorting with CD138+ MicroBeads (Miltenyi Biotec).
Viability and apoptosis assay
Cell lines were plated in quintuplicate in 96-well ﬂat-bottom plates with
idelalisib, CZC24832 and duvelisib. These were incubated for 24–72 h with
viable numbers being measured using Cell Titre GLO (Promega, South-
ampton, UK). Flow cytometry was performed to measure apoptosis using
the CyFlow Cube 6 ﬂow cytomter (Sysmex, Milton Keynes, UK). For
measuring viability, samples were collected and stained with Annexin
V and propidium iodide (PI), followed by detection via ﬂow cytometry.
Data were then normalised to vehicle controls. All data points are
represented as the mean with s.d.
Western immunoblotting
SDS–polyacrylamide gel electrophoresis and Western analyses were per-
formed as described previously.16 Brieﬂy, whole-cell lysates were extracted
using radio immunoprecipitation assay buffer method and SDS–poly-
acrylamide gel electrophoresis separation was performed. Protein was
transferred to PVDF membrane and Western blot analysis performed with
the indicated anti-sera according to manufacturer's guidelines. Detection
was performed by electrochemical luminescence.
BMSC/ﬁbronectin–MM cell adhesion assay
BMSCs were grown in 96-well tissue culture plates at 2 × 104 cells per well
in 200 µl of media. MM cells were incubated with 2.5 μM calcein AM for 1 h
at 37°C and 5% CO2. The ﬂuorescence-labelled MM cells were added to
BMSC plates and incubated for the indicated time points. Non-adherent
calcein-labelled cells were removed by gently washing and adherent cells
were quantitated in a ﬂuorescence multi-well plate reader. For MM cell
adhesion onto ﬁbronectin (FN), 96-well plates were coated with 10 mg/ml
FN for 1 h before the ﬂuorescence-labelled MM cells were added. Non-
adherent calcein-labelled cells were removed by gently washing and
adherent cells were quantitated in a ﬂuorescence multi-well plate reader.
Lentiviral transduction
pCDH-luciferase-T2A-mCherry was kindly gifted from Professor Dr med
Irmela Jeremias, Helmholtz Zentrum München, Munchen, Germany.17
Lentivirus particles generated using this construct were produced as
previously described.18 Lentiviral stocks were concentrated using Amicon
Ultra centrifugal ﬁlters and titres were determined using Lenti-X qRT-PCR
titration kit (CloneTech, Oxford, UK). U266 cells were plated at a density of
5 × 104 per well in a 12-well plate and expanded. U226 cells expressing
mCherry (U266-luc) were sorted on a FACSAria (BD, Oxford, UK).
Migration assays
Migration assays were performed in triplicate in transwell permeable plates
with 4.0 μM pores (Neuroprobe, Gaithersburg, MD, USA). The lower
compartment contained 30 μl of conditioned media or serum-free media
supplemented with 100 ng/ml stromal cell derived factor 1 (SDF1).
Myeloma cells were applied to the upper compartment and allowed to
Figure 1. Inhibition of PI3Kδ and PI3Kγ subunits in MM proliferation. (a) Western blot analysis of PI3Kδ and PI3Kγ subunits in MM cell lines and
MM primary cells. Blots were probed with β-actin to show sample loading. (b) MM primary cells were treated with idelalisib (1 μM), CZC24832
(1 μM) and duvelisib (1 μM) for 72 h and then assessed for cell viability using CellTiter Glo. (c) MM primary cells were treated with idelalisib
(1 μM), CZC24832 (1 μM) and duvelisib (1 μM) for 72 h and then assessed for apoptosis by PI/Annexin V staining (n= 4).
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migrate for 4 h. The quantity of viable migrated myeloma cells was
determined by counting using trypan blue exclusion and expressed as a
percentage of the input.
Real-time PCR
Total RNA was extracted from cells using the ReliaPrep RNA extraction kit
from Promega according to the manufacturer’s instructions. Reverse
transcription was performed using the qPCRBIO cDNA synthesis kit (PCR
Biosystems, London, UK). Relative quantitative real-time PCR using
qPCRBIO SyGreen Mix (PCR Biosystems) was performed on complimentary
DNA generated from the reverse transcription of puriﬁed RNA. After pre-
ampliﬁcation (95°C for 2 min), the PCRs were ampliﬁed for 45 cycles (95°C
for 15 s, 60°C for 10 s and 72°C for 10 s) on a 384-well LightCycler 480
(Roche, Burgess Hill, UK). Each messenger RNA expression was normalised
against β-actin messenger RNA expression.
MM xenograft model
For this study NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG) mice from The
Jackson Laboratory, Bar Harbour, ME, USA were used. The NSG mice were
maintained under speciﬁc pathogen-free conditions. All animal experi-
ments were performed in accordance with UK Home Ofﬁce regulations. For
the MM xenograft model, 0.5 × 106 U266-luc cells were intravenously
injected into non-irradiated 6–8-week-old NSG mice. On day 4 after
intravenously injection of U266 cells, NSG mice were treated with duvelisib
at 15 mg/kg per day via intraperitoneal injection. Mice were treated for
10 days with duvelisib (n= 6) or vehicle control (n= 6).
For lentiviral experiments, either control knockdown (Con KD) or target
gene KD luciferase expressing U266 cells were intravenously injected into
non-irradiated 6–8-week-old NSG mice. When clinical signs of illness
became apparent mice were killed by exposure to CO2. Bone marrow was
harvested and analysed for human CD45. All mice were monitored via
in vivo bioluminescent imaging (Bruker, Coventry, UK).
Statistical analysis
For Western blotting experiments, data are representative of three
independent experiments. For all in vitro assays, a Mann–Whitney U-test
was performed to assess statistical signiﬁcance against the control group.
The Mantel–Cox test was used to analyse Kaplan–Meier survival curves.
Figure 2. Knockdown of PI3K isoforms in MM. (a) MM1s cells and RPMI8226 were transduced with lentivirus targeted to PI3Kδ and PI3Kγ or
control shRNA for 72 h. RNA was extracted and analysed for either PI3Kδ or PI3Kγ messenger RNA expression by real-time PCR. GAPDH was
used to normalise RNA values. (b) MM1s cells and RPMI8226 were transduced with lentivirus targeted to PI3Kδ and PI3Kγ or control shRNA for
5 days. Cells were then assayed for viability by Cell Titre Glo assay. (c) MM1s cells and RPMI8226 were transduced with lentivirus targeted to
PI3Kδ and PI3Kγ or control shRNA for 5 days. Cells were then assessed for apoptosis by PI/Annexin V staining.
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RESULTS
Inhibition of PI3K PI3Kδ and PI3Kγ subunits reduces MM
proliferation and survival
To verify that PI3Kδ and PI3Kγ subunits are expressed in MM cells
we examined protein expression of both isoforms using Western
blotting in primary MM samples and MM cell lines. Figure 1a
shows that both isoforms are expressed in MM cell lines and
primary MM cells. To understand the signiﬁcance of PI3Kδ and/or
PI3Kγ in MM we investigated the effects of PI3K inhibitors
(idelalisib (PI3Kδ), CZC24832 (PI3Kγ) and duvelisib (PI3Kδ/γ)) on
MM cell death assays. As idelalisib and duvelisib are active at
nanomolar concentrations19,20 and low micromolar concentra-
tions are achievable in vivo,21,22 we performed in vitro experiments
using idelalisib (1 μM), CZC24832 (1 μM) and duvelisib (1 μM). Drug
was added to assays for 72 h and MM cell death was measured
using the CellTiter Glo assay. At the concentration used the MM
primary cells have increased cell death after dosing with duvelisib
(Po0.01; Figure 1b). Furthermore, we show that duvelisib had a
greater effect on primary MM apoptosis than either idelalisib or
CZC24832 (Figure 1c).
Combined knockdown of PI3Kδ/γ isoforms reduces survival and
increases apoptosis MM cell lines
To help determine the dominant PI3K isoform in MM proliferation
and downstream signalling we used targeted shRNA KD of PI3Kδ
and PI3Kγ messenger RNA. Results conﬁrm that the PI3Kδ and
PI3Kγ shRNA caused signiﬁcant KD of PI3Kδ and PI3Kγ messenger
RNA in MM1s and RPMI8226 cells (Figure 2a). Figure 2b shows that
PI3Kδ had no effect on MM1s or RPMI8226 cell line viability,
however PI3Kγ KD had a signiﬁcant effect on MM1s but not
RPMI8226 cells. Furthermore, combined knockdown of PI3Kδ
and PI3Kγ had a signiﬁcant effect in reducing in vitro survival of
both MM1s and RPMI8226 cells. Figure 2c shows that combined
knockdown of PI3Kδ and PI3Kγ also increased apoptosis in both
MM1s and RPMI8226 cells.
Combined KD of PI3Kδ and PI3Kγ is more effective at inhibiting
AKT phosphorylation than inhibition of either isoform alone
As PI3Kδ and PI3Kγ are known to activate AKT, we analysed the
phosphorylation status of s473 in response to idelalisib, CZC24832
and duvelisib. Drugs were used at a dose of 1 µM. Figure 3a shows
that duvelisib inhibits the constitutive phosphorylation of s473
in MM1S cells, U266 cells and primary MM samples. However,
idelalisib (P3Kδ) or CZC24832 (PI3Kγ) had no inhibitory effect on
AKT phosphorylation on U266, MM1s and primary MM cells at the
drug concentration used. In addition, no inhibition of MAPK
phosphorylation was observed with any of the drugs. Figure 3b
shows that in MM1s cells duvelisib inhibits constitutive phosphor-
ylation of AKT at s473 in a dose-dependent manner. Next we
examined if knockdown of either PI3Kδ or PI3Kγ could inhibit AKT
phosphorylation. Figure 3c shows that combined KD of PI3Kδ and
PI3Kγ was more effective at inhibiting AKT phosphorylation than
knockdown of either isoform alone. These results demonstrate
that inhibiting both PI3Kδ and PI3Kγ using duvelisib or by genetic
knockdown has a greater effect on AKT s473 inhibition than PI3Kδ
or PI3Kγ inhibition alone.
MM adhesion to BMSC is regulated by both PI3Kδ and PI3Kγ, with
PI3Kγ exclusively mediating ﬁbronectin adhesion and MM cell
migration
The interaction between the myeloma cells and their microenvir-
onment in the bone marrow is central in the regulation of tumour
survival and progression. Surface adhesion molecules on MM cells
have been shown to mediate cellular adhesion molecule drug
resistance.23 We investigated the roles of PI3Kδ and PI3Kγ on MM
cell adhesion to primary BMSCs to determine if suppression of the
Figure 3. Inhibition of PI3Kδ and PI3Kγ inhibits AKT phosphorylation. (a) MM1s, U266, MM#1 and MM#2 cells were incubated with idelalisib
(1 μM), CZC24832 (1 μM) and duvelisib (1 μM) for 4 h after which protein was extracted. Samples were subsequently analysed for phospho-AKT
and phospho-MAPK responses using Western blotting. Blots were re-probed for total AKT and MAPK to conﬁrm sample loading. (b) MM1s
were incubated with increasing doses of duvelisib for 4 h after which protein was extracted. Samples were then analysed for phospho-AKT
and phospho-MAPK response using Western blotting. Blots were re-probed for total AKT and MAPK to conﬁrm sample loading. (c) MM1s cells
were transduced with lentivirus targeted to PI3Kδ and PI3Kγ or control shRNA for 72 h. Protein was extracted and analysed for phospho-AKT
and phospho-MAPK via Western blotting. Total AKT and MAPK were used as loading controls.
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PI3K pathway could inﬂuence the engagement of cell surface
integrins. MM cells were cultured with BMSCs at a ratio of 4:1 and
cell cultures were incubated with idelalisib (PI3Kδ), CZC24832
(PI3Kγ) and duvelisib (PI3Kδγ; all 1 µM) for 2 h before calcein AM
ﬂuorescence-based adhesion assays were used. Duvelisib, but not
idelalisib or CZC24831, inhibited MM cell lines and primary MM
cell adhesion to BMSC (Figures 4a and b). This data suggest that
both isoforms function in the regulation of MM adhesion to BMSC
through a combinatorial mechanism.
Inhibiting MM adhesion to BMSCs via the VLA4-VCAM/FN
interaction is associated with increased tumour sensitivity to
chemotherapy.24 We next examined if either PI3Kδ or PI3Kγ KD in
MM cells could inhibit MM adhesion to FN. Figure 4c shows that
PI3Kγ KD alone or in combination with PI3Kδ KD inhibits MM
adhesion to FN. PI3Kδ KD had no effect on MM cell adhesion to
FN. Next we wanted to determine if idelalisib (PI3Kδ), CZC24832
(PI3Kγ) and duvelisib could inhibit VLA4-VCAM/FN interactions.
At the 1 µM dose used MM adherence to FN-coated plates was
only inhibited by duvelisib (Figure 4d).
PI3K has been shown to regulate migration of immune
cells including mast cells and neutrophils.25,26 We hypothesised
that inhibition of PI3Kδ and/or PI3Kγ subunits would inhibit
MM migration towards SDF1 containing media. Figure 4e shows
that MM cells migrate towards SDF1 supplemented media.
Duvelisib (1 µΜ) inhibited MM cell migration, however, this effect
is not inhibited by either CZC24832 or idelalisib at similar drug
concentrations.
Together PI3Kδ/γ regulates IL-6-induced AKT activation in MM
IL-6 has been identiﬁed as a key cytokine supporting growth and
proliferation of MM, as well as being shown to induce PI3K/AKT
signalling.27 We therefore examined the effects of PI3Kδ and PI3Kγ
inhibition on IL-6-induced activation of AKT and MAPK pathways.
Figure 5a shows that duvelisib, but not CZC24832 and idelalisib,
inhibits IL-6-induced AKT phosphorylation in serum-starved MM1s
and primary MM samples. Figure 5b shows that duvelisib-induced
inhibition is dose-dependent. To conﬁrm these results we tested
IL-6-induced activation of AKT in PI3Kδ KD, PI3Kγ KD and
Figure 4. MM adhesion to BMSC and ﬁbronectin is regulated by PI3Kδ. (a, b) MM cell lines and MM primary cells were treated with idelalisib
(1 μM), CZC24832 (1 μM) and duvelisib (1 μM) for 4 h and then stained with calcein AM. Stained cells were added to BMSC on 96-well plates for a
4 h incubation. Non-adherent cells were removed and ﬂuorescence was measured. (c) MM1s and RPMI8226 cells were transduced with
lentivirus targeted to PI3Kδ and PI3Kγ or control shRNA for 72 h. Transduced cells were stained with calcein AM and added to BMSC on a
96-well plate for a 4 h incubation. Non-adherent cells were removed and ﬂuorescence was measured. (d) RPMI8226 and MM#2 primary cells
were treated with idelalisib (1 μM), CZC24832 (1 μM) and duvelisib (1 μM) for 4 h and then stained with calcein AM. Stained cells were added
96-well plates coated with ﬁbronectin for a 4 h incubation. Non-adherent cells were removed and ﬂuorescence was measured. (e) MM cell
lines were incubated with idelalisib (1 μM), CZC24832 (1 μM) and duvelisib (1 μM) for 4 h and subsequently treated with calcein AM. Cells were
then placed in the upper well of a 5 μM transwell plate. The lower chamber contained 30 µl of serum-free media or serum-free media
supplemented with SDF1 (100 ng/ml) for 4 h and MM cell migration was then assessed using ﬂuorescent plate reader.
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combined PI3Kδγ KD MM1s cells. Figure 5c shows that isolated
PI3Kδ KD or isolated PI3Kγ KD failed to block IL-6-induced AKT
activation; however combined PI3Kδγ KD completely blocks
IL-6-induced AKT activation.
BMSCs do not protect MM cells from PI3Kδ/γ inhibition
It has been shown that BMSC can protect MM cells from
chemotherapy-induced apoptosis,28 so we decided to assess the
efﬁcacy of duvelisib in MM under BMSC co-culture conditions.
Accordingly, we cultured primary MM cells with BMSC (ratio 4:1)
in the presence or absence of duvelisib, CZC24832 or idelalisib
(all 1 µM). Duvelisib induced apoptosis in primary MM cells
(Figures 5d and e). These ﬁndings show that inhibition of PI3Kδ/γ
with duvelisib induces apoptosis in MM cells even when
co-cultured with BMSCs.
PI3Kδ/γ inhibition signiﬁcantly reduces engraftment and tumour
burden in vivo
In order to track MM disease progression in vivo we transduced
U266 cells with a luciferase construct, which is detectable
by bioluminescence in live animals. U266-luc cells were then
transduced via lentiviral knockdown targeting of PI3Kδ and PI3Kγ.
NSG mice (6–8 weeks) were injected with 0.5 × 106-modiﬁed U266-
luc cells from control, PI3Kδ, PI3Kγ or combined PI3Kδ/γ KD.
At 21 days post injection, we analysed engraftment of U266-Luc
cells by bioluminescence. Reduced engraftment was observed
in animals transplanted with PI3Kδ, PI3Kγ or PI3Kδ/γ KD U226-luc
Figure 5. PI3Kδ/γ regulate IL-6-induced AKT activation in MM. (a) MM1s and primary MM were incubated with idelalisib (1 μM), CZC24832
(1 μM) and duvelisib (1 μM) for 4 h and then stimulated with IL-6 for 15 min before protein extraction. Samples were then analysed for
phospho-AKT and phospho-MAPK response using Western blotting. Blots were re-probed to conﬁrm sample loading. (b) MM1s and RPMI8226
cells were incubated with increasing doses of duvelisib for 6 h after which they were stimulated with and without 100 ng/ml IL-6 for 15 min.
Protein was extracted and analysed for phospho-AKT and phospho-MAPK via Western blotting. Total AKT and MAPK were used as loading
controls. (c) MM1s cells were transduced with lentivirus targeted to PI3Kδ and PI3Kγ or control shRNA for 72 h and then treated with IL-6 for
15 min. Protein was extracted and analysed for phospho-AKT and phospho-MAPK via Western blotting. Total AKT and MAPK were used as
loading controls. (d, e) MM primary cells were incubated with BMSC for 24 h and then treated with idelalisib (1 μM), CZC24832 (1 μM) and
duvelisib (1 μM) for 24 h, then assessed for apoptosis by PI/Annexin V staining.
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cells compared to control KD U226-luc cells (Figure 6a).
Figure 6b shows that animals transplanted with PI3Kδ, PI3Kγ or
PI3Kδγ KD cells all have increased survival compared to control KD
NSG mice.
To examine the effect of duvelisib in vivo, we injected mice
with 0.5 × 106 U266-luc cells via the tail vein. Mice were treated
daily for 10 days with duvelisib (15 mg/kg on days 5–14 following
transplant). On day 18 after transplant (4 days after completion
of the 10- day duvelisib treatment), duvelisib-treated animals
had reduced tumour burden when compared to vehicle control
treated animals, as measured by bioluminescence (Figure 6c).
Furthermore, Kaplan–Meier analysis shows signiﬁcant survival
improvement in the duvelisib-treated group when compared to
the control-treated group (Figure 6d).
DISCUSSION
The PI3K p110 α, β, δ and γ subunits have all been shown to be
constitutively expressed in MM.11 In this study we investigated the
role of the PI3Kγ catalytic subunit and the effects of inhibiting PI3Kγ
alone or in combination with PI3Kδ inhibition. We were interested to
consider the biological rationale for the potential use of a clinical
availability of a PI3Kδ inhibitor (idelalisib) or a combined PI3Kδ/γ
inhibitor (duvelisib) in patients with MM. Here we report that drug
Figure 6. Inhibition of PI3Kδ/γ in vivo leads to reduced engraftment and increased survival. (a, b) U266-luc were transduced with lentivirus
targeted to PI3Kδ and PI3Kγ or PI3Kδ/γ or control shRNA for 96 h. About 0.5 × 106 cells lentiviral transduced U266-luc were subsequently were
i.v. injected into NSG mice via the tail vein. (a) Bioluminescence (BLI) was used to track the U266-luc cells in vivo. (b) Survival of the NSG mice is
represented by a Kaplan–Meier plot. (c, d) About 0.5x106 cells were i.v. injected into NSG mice. At day 5 after i.v. injection mice were treated
i.p. with IP1-145 (15 mg/kg per day) or vehicle control. (c) BLI was used to track the U266-luc cells in vivo. (d) Survival of the NSG mice is
represented by a Kaplan–Meier plot.
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inhibition of the PI3Kγ subunit reduces MM proliferation and survival.
Furthermore, combined drug inhibition of PI3Kγ and PI3Kδ appears
more cytotoxic to MM cells than inhibition of either isoform alone, an
observation that is supported by data from isoform-speciﬁc shRNA-
targeted KD experiments. This data are consistent with our ﬁnding that
combined KD of PI3Kδ and PI3Kγ is more effective at inhibiting AKT
phosphorylation than inhibition of either isoform alone. Functionally
we found that MM adhesion to BMSC is regulated by both PI3Kδ and
PI3Kγ, but FN adhesion and SDF1-mediated migration appear to be
exclusively PI3Kγ-mediated processes. Moreover and of potential
clinical relevance, BMSCs do not protect MM cells from combined
PI3Kδ/γ inhibition. In vivo-combined PI3Kδ/γ inhibition signiﬁcantly
reduces MM engraftment. Finally, in vivo-combined PI3Kδ/γ inhibitor
treatment reduces tumour burden and improves survival in animals
with established MM. Taken together our data suggest that PI3Kδ and
PI3Kγ appear to have both distinct and overlapping functions within
MM and that inhibition of both isoforms simultaneously may result in
the more effective form of treatment than single isoform inhibition
alone.
AKT activity in MM is associated with poor patient prognosis and
resistance to currently available treatment.1,2 It is therefore a logical
strategy to inhibit upstream AKT activators, the primary of which is
PI3K. Previously, the PI3Kδ inhibitor idelalisib has been shown to
reduce MM cell proliferation, however its effect on primary MM tissue
had not been investigated.11 Moreover, despite the efﬁcacy of pan-
PI3K inhibitors on MM cells, these compounds appear to be poorly
tolerated in vivo due to their lack of speciﬁcity and non-MM cell
effects.29 Therefore given the early-phase clinical trial results with the
dual PI3Kδ/γ inhibitor duvelisib, which shows the drug to be well
tolerated in patients with lymphoma,20 we assessed the feasibility of
dual PI3Kδ/γ inhibition in MM. In in vitro experiments we selected
concentrations of drugs known to be biologically active but also
achievable in vivo.21 Adhesion of MM cells to the bone marrow has
been shown to be of critical importance regarding cell adhesion-
mediated drug resistance.23,30 In this study, we show that MM cell
adhesion to BMSCs is signiﬁcantly affected by suppression of the
PI3Kδ/γ catalytic subunits in experiments with both targeted shRNA
knockdown and drug inhibition with duvelisib. Lentiviral knockdown
demonstrated the speciﬁc roles of the PI3K subunits, with PI3Kγ shown
to have a more signiﬁcant role in myeloma cell adhesion and
migration.
The PI3K pathway contributes to the regulation of many cellular
functions, including survival and proliferation, by catalysing the
phosphorylation of phosphoinositide lipids.31 Aberrant PI3K pathway
activation has been associated with several cancer types32–34
including MM and other haematological malignancies.11,31,35 Here
we showed via Western blotting that the activation of this pathway is
further upregulated in cell lines and primary samples when stimulated
with the cytokine IL-6. IL-6 secreted from the BMSCs in response to
MM has been shown to play a key role in MM pathogenesis,36 acting
as a growth factor for MM cells and promoting drug resistance in the
bone marrow microenvironment.37,38 In addition, we show that
lentiviral targeting of both PI3Kδ/γ subunits inhibits IL-6-induced AKT
activation, whereas singular δ and γ KD does not have a signiﬁcant
effect. We therefore hypothesise that targeting both PI3Kδ/γ would
be the preferred strategy to suppress the PI3K pathway in MM cells.
Furthermore, we provide evidence that this should remain the case
even when MM is subject to bone marrow-induced protection.
Lentiviral KD of PI3Kδ or γ or δγ in combination in vivo resulted in a
reduction of disease burden and subsequent extension of survival in all
conditions in comparison to the control. Percentage engraftment was
signiﬁcantly reduced in PI3Kγ-KD compared to the control KD, which
suggests that targeting the PI3Kγ subunit could be a mechanism of
reducing engraftment or even mobilising the MM cells from the bone
marrow into the peripheral blood. The idea that PI3Kγ coordinates
migratory signals is not novel and thus ﬁts with the idea that targeting
this isoformmay be important in ﬂushing the MM cells out of the bone
marrow on which their survival is dependent.
Finally, we showed that treatment of MM-engrafted NSG mice
with duvelisib resulted in a signiﬁcant increase in the survival of
the animals despite allowing for an engraftment period and
treatment time of only 10 days. Tumour burden was shown
not only to slow, inferring a reduction in proliferation, but actually
reduce suggesting in vivo anti-MM activity for the drug. We did
not conduct experiments to establish a formal drug-dosing
strategy although it is encouraging from a clinical perspective
that in other forms of haemic malignancy daily continuous dosing
of PI3K inhibitors appears to generally well tolerated by patients.22
In conclusion, the data reported here provide a molecular
mechanistic rationale for the clinical evaluation of duvelisib (and
other combined PI3K γ/δ inhibitors) in patients with MM.
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